YMAB logo

Y-mAbs Therapeutics (YMAB)

Profile

Full Name

Y-mAbs Therapeutics, Inc.

Ticker Symbol

YMAB

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

September 21, 2018

Indexes

Not included

Website

http://www.ymabs.com

Employees

104

Key Details

Price

$4.54(-15.14%)

Market cap

$205.29M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$87.69M(+3.38% YoY)

Annual EPS

-$0.67(-36.73% YoY)

PE ratio

-

Next earnings date

May 7, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$4.54
YMAB price is $4.54

30-Day Relative Volume

0.83
YMAB 30-day relative volume is 0.83

Price Performance

Price Today change

-15.14%
YMAB price is down -15.14% today

Price YTD change

-42.02%
YMAB price is down -42.02% since January 1st

Price 1-year change

-70.01%
YMAB price is down -70.01% year-on-year

Price 3-year change

-64.59%
YMAB price is down -64.59% over the past 3 years

Price Range

Price All-time high

$55.22
YMAB price is currently -91.78% below its historical high of $55.22

Price 3-year low

$2.70
YMAB price is currently +68.15% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$205.29M
YMAB market capitalization is $205.29 million

Market cap 3-year change

-63.37%
YMAB market capitalization is down -63.37% over the past 3 years

Market cap All-time high

$2.20B
YMAB market capitalization is currently -90.66% below its historical high of $2.20 billion

Market cap sector rank

58.14%
YMAB market capitalization is higher than 58.14% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+3.11%
YMAB shares outstanding is up +3.11% year-on-year

Shares Outstanding 3-Year Change

+3.44%
YMAB shares outstanding is up +3.44% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.26
YMAB beta is 1.26

200-day SMA

$9.97
YMAB price is currently -54.47% below its 200-day simple moving average

50-day SMA

$5.18
YMAB price is currently -12.34% below its 50-day simple moving average

RSI

45.42
YMAB 14-day relative strength index is 45.42

Volume

0.83
YMAB 30-day relative volume is 0.83

ATR

$0.45
YMAB average true range is $0.45

10-day Historical Volatility

127.14%
YMAB 10-day historical volatility is 127.14%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$87.69M
YMAB annual revenue is $87.69 million

Revenue Analysts estimate

$83.53M
YMAB annual revenue is currently +4.97% higher than the consensus analysts' forecast

Revenue 1-year change

+3.38%
YMAB annual revenue is up +3.38% year-on-year

Revenue Sector rank

55.08%
YMAB annual revenue is higher than 55.08% of companies in Healthcare sector

EPS

EPS

-$0.67
YMAB annual earnings per share is -$0.67

EPS Analysts estimate

-$0.90
YMAB annual earnings per share is currently -25.46% lower than the consensus analysts' forecast

EPS 1-year change

-36.73%
YMAB annual earnings per share is down -36.73% year-on-year

EPS Sector rank

64.04%
YMAB annual earnings per share is higher than 64.04% of companies in Healthcare sector

Profit

Gross profit

$72.43M
YMAB annual gross profit is $72.43 million

Gross margin

82.61%
YMAB annual gross profit margin is 82.61%

Operating profit

-$31.20M
YMAB annual operating income is -$31.20 million

Operating margin

-35.58%
YMAB annual operating profit margin is -35.58%

Net income

-$29.67M
YMAB annual net profit is -$29.67 million

Net margin

-33.83%
YMAB annual net profit margin is -33.83%

Expenses

Total expenses

$118.89M
YMAB annual total expenses is $118.89 million

Operating expenses

$103.64M
YMAB annual total operating expenses is $103.64 million

Cost of goods sold

$15.25M
YMAB annual cost of goods sold is $15.25 million

Selling, general & administrative expenses

$54.65M
YMAB annual SGA is $54.65 million

Depreciation and amortization

$535.00K
YMAB annual depreciation & amortization is $535.00 thousand

Interest expense

-
YMAB annual interest expense value is unknown

Income tax

-$146.00K
YMAB annual income tax is -$146.00 thousand

EBIT & EBITDA

EBIT

-$31.20M
YMAB annual earnings before interest & taxes is -$31.20 million

EBITDA

-$30.67M
YMAB annual EBITDA is -$30.67 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$119.90M
YMAB annual total assets is $119.90 million

Non current assets

$21.39M
YMAB annual long term assets is $21.39 million

Current assets

$98.51M
YMAB annual total current assets is $98.51 million

Cash and cash equivalents

$67.23M
YMAB annual cash & cash equivalents is $67.23 million

Accounts receivable

$19.69M
YMAB annual accounts receivable is $19.69 million

Inventory

$7.21M
YMAB annual inventory is $7.21 million

Liabilities

Total liabilities

$27.90M
YMAB annual total liabilities is $27.90 million

Long term liabilities

$4.20M
YMAB annual total long term liabilities is $4.20 million

Current liabilities

$23.70M
YMAB annual total current liabilities is $23.70 million

Accounts payable

$6.66M
YMAB annual accounts payable is $6.66 million

Debt

Total debt

$820.00K
YMAB annual total debt is $820.00 thousand

Total debt 1-year change

-42.21%
YMAB annual total debt is down -42.21% year-on-year

Long term debt

$190.00K
YMAB annual long term debt is $190.00 thousand

Short term debt

$630.00K
YMAB annual short term debt is $630.00 thousand

Equity & Capital

Shareholders equity

$92.00M
YMAB annual stockholders equity is $92.00 million

Book value

$92.00M
YMAB annual book value is $92.00 million

Retained earnings

-$487.14M
YMAB annual retained earnings is -$487.14 million

Working capital

$74.81M
YMAB annual working capital is $74.81 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$15.71M
YMAB annual cash flow from operations is -$15.71 million

Cash from operations 1-year change

+42.3%
YMAB annual cash flow from operations is up +42.3% year-on-year

Cash from investing

$0.00
YMAB annual cash flow from investing activities is $0.00

Cash from investing 1-year change

0%
YMAB {parameterFullLabel} has remained unchanged year-on-year

Cash from financing

$4.31M
YMAB annual cash flow from financing activities is $4.31 million

Cash from financing 1-year change

+4211%
YMAB annual cash flow from financing activities is up +4211% year-on-year

CAPEX

CAPEX

-
YMAB annual capital expenditures value is unknown

CAPEX 1-year change

-
YMAB annual capital expenditures 1-year change is unknown

Free Cash Flow

Free cash flow

-$15.71M
YMAB annual free cash flow is -$15.71 million

Free cash flow 1-year change

+42.3%
YMAB annual free cash flow is up +42.3% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

82.61%
YMAB annual gross profit margin is 82.61%

Operating margin

-35.58%
YMAB annual operating profit margin is -35.58%

Net margin

-33.83%
YMAB annual net profit margin is -33.83%

ROA & ROE

ROA

-23.95%
YMAB annual return on assets is -23.95%

ROE

-30.74%
YMAB annual return on equity is -30.74%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
YMAB price to earnings ratio value is unknown

PE ratio Sector rank

-
YMAB price to earnings ratio is unknown

PB Ratio

PB ratio

2.23
YMAB price to book ratio is 2.23

PB ratio Sector rank

66.17%
YMAB price to book ratio is higher than 66.17% of companies in Healthcare sector

PS Ratio

PS ratio

2.34
YMAB price to sales ratio is 2.34

PS ratio Sector rank

46.28%
YMAB price to sales ratio is higher than 46.28% of companies in Healthcare sector

Enterprise value

Enterprise value

$138.88M
YMAB enterprise value is $138.88 million

Enterprise value Sector rank

53.68%
YMAB enterprise value is higher than 53.68% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-4.53
YMAB EV/EBITDA is -4.53

EV/EBITDA Sector rank

19.67%
YMAB EV/EBITDA is higher than 19.67% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

4.16
YMAB annual current ratio is 4.16

Quick ratio

3.85
YMAB annual quick ratio is 3.85

Leverage

Debt to equity

0.00
YMAB annual debt to equity ratio is 0.00

Interest coverage ratio

-
YMAB annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

3
YMAB piotroski f-score is 3

Altman Z-Score

-0.65
YMAB altman z-score is -0.65

Analyst ratings

Recent major analysts updates

Mar 21, 25 HC Wainwright & Co.
Buy
Mar 5, 25 Truist Securities
Buy
Mar 5, 25 Morgan Stanley
Underweight
Mar 5, 25 B of A Securities
Neutral
Jan 13, 25 HC Wainwright & Co.
Buy
Dec 11, 24 HC Wainwright & Co.
Buy
Dec 5, 24 Brookline Capital
Buy
Nov 18, 24 Oppenheimer
Outperform
Nov 15, 24 HC Wainwright & Co.
Buy
Sep 10, 24 Wedbush
Outperform

Institutional Ownership

Similar stocks

AVIR logo
Atea Pharmaceuticals (AVIR)
RCEL logo
AVITA Medical (RCEL)
HUMA logo
Humacyte (HUMA)
ABEO logo
Abeona Therapeutics (ABEO)
CERS logo
Cerus (CERS)
VSTM logo
Verastem (VSTM)
STIM logo
Neuronetics (STIM)
MRVI logo
Maravai LifeSciences Holdings (MRVI)
CMPX logo
Compass Therapeutics (CMPX)
  • What is the ticker symbol for Y-mAbs Therapeutics?
  • Does Y-mAbs Therapeutics pay dividends?
  • What sector is Y-mAbs Therapeutics in?
  • What industry is Y-mAbs Therapeutics in?
  • What country is Y-mAbs Therapeutics based in?
  • When did Y-mAbs Therapeutics go public?
  • Is Y-mAbs Therapeutics in the S&P 500?
  • Is Y-mAbs Therapeutics in the NASDAQ 100?
  • Is Y-mAbs Therapeutics in the Dow Jones?
  • When was Y-mAbs Therapeutics's last earnings report?
  • When does Y-mAbs Therapeutics report earnings?
  • Should I buy Y-mAbs Therapeutics stock now?

What is the ticker symbol for Y-mAbs Therapeutics?

The ticker symbol for Y-mAbs Therapeutics is NASDAQ:YMAB

Does Y-mAbs Therapeutics pay dividends?

No, Y-mAbs Therapeutics does not pay dividends

What sector is Y-mAbs Therapeutics in?

Y-mAbs Therapeutics is in the Healthcare sector

What industry is Y-mAbs Therapeutics in?

Y-mAbs Therapeutics is in the Biotechnology industry

What country is Y-mAbs Therapeutics based in?

Y-mAbs Therapeutics is headquartered in United States

When did Y-mAbs Therapeutics go public?

Y-mAbs Therapeutics's initial public offering (IPO) was on September 21, 2018

Is Y-mAbs Therapeutics in the S&P 500?

No, Y-mAbs Therapeutics is not included in the S&P 500 index

Is Y-mAbs Therapeutics in the NASDAQ 100?

No, Y-mAbs Therapeutics is not included in the NASDAQ 100 index

Is Y-mAbs Therapeutics in the Dow Jones?

No, Y-mAbs Therapeutics is not included in the Dow Jones index

When was Y-mAbs Therapeutics's last earnings report?

Y-mAbs Therapeutics's most recent earnings report was on Mar 4, 2025

When does Y-mAbs Therapeutics report earnings?

The next expected earnings date for Y-mAbs Therapeutics is May 7, 2025

Should I buy Y-mAbs Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page